The Dual Reuptake Wars
The Carlat Psychiatry Report, Volume 3, Number 1, January 2005
Daniel Carlat, MD
Dr. Carlat has disclosed that he has no significant relationships with or financial interests in any commercial companies pertaining to this educational activity.
I know what you’re thinking, “This is going to be a Cymbalta vs. Effexor article, and Cymbalta will get another TCR drubbing as it did last year.” Not quite. In fact, there are two major battles to be reviewed: Effexor vs. Cymbalta, but probably more relevant, Effexor vs. Lexapro.